AU Patent

AU2025203171A1 — A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis

Assigned to Merck Patent GmbH · Expires 2025-05-22 · 1y expired

What this patent protects

A SUBSTITUTED AMINO-PYRIDINE COMPOUND FOR USE IN A METHOD FOR TREATMENT AND PREVENTION OF MULTIPLE SCLEROSIS ABSTRACT The invention provides methods, compositions, and medical kits for treating and preventing multiple sclerosis using 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimid…

USPTO Abstract

A SUBSTITUTED AMINO-PYRIDINE COMPOUND FOR USE IN A METHOD FOR TREATMENT AND PREVENTION OF MULTIPLE SCLEROSIS ABSTRACT The invention provides methods, compositions, and medical kits for treating and preventing multiple sclerosis using 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4 yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one or a pharmaceutically acceptable salt thereof according to preferred dosing regimens. 21721125_1 (GHMatters) P115057.AU.1

Drugs covered by this patent

Patent Metadata

Patent number
AU2025203171A1
Jurisdiction
AU
Classification
—
Expires
2025-05-22
Drug substance claim
No
Drug product claim
No
Assignee
Merck Patent GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.